Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.

Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA.

Neuropsychopharmacology. 2020 Feb 3. doi: 10.1038/s41386-020-0628-9. [Epub ahead of print]

PMID:
32015461
2.

An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS.

Kegeles LS, Ciarleglio A, León-Ortiz P, Reyes-Madrigal F, Lieberman JA, Brucato G, Girgis RR, de la Fuente-Sandoval C.

Schizophr Res. 2019 Sep 12. pii: S0920-9964(19)30413-X. doi: 10.1016/j.schres.2019.09.004. [Epub ahead of print]

PMID:
31522867
3.

Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study.

Giménez M, Cano M, Martínez-Zalacaín I, Real E, Alonso P, Segalàs C, Munuera J, Kegeles LS, Weinstein JJ, Xu X, Menchón JM, Cardoner N, Soriano-Mas C, Fullana MA.

Eur Arch Psychiatry Clin Neurosci. 2019 Aug 20. doi: 10.1007/s00406-019-01056-3. [Epub ahead of print]

PMID:
31432262
4.

Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS.

Psychiatry Res. 2019 May;275:78-85. doi: 10.1016/j.psychres.2019.03.018. Epub 2019 Mar 12.

PMID:
30884334
5.

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.

Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman J, Krystal JH, Corlett PR.

Neuroimage Clin. 2019;22:101739. doi: 10.1016/j.nicl.2019.101739. Epub 2019 Feb 28.

6.

Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain.

Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, Bellei C, Valmadre A, Vanegas N, Kegeles LS, Brucato G, Kang UJ, Sulzer D, Zecca L, Abi-Dargham A, Horga G.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5108-5117. doi: 10.1073/pnas.1807983116. Epub 2019 Feb 22.

7.

Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder.

Kegeles LS, Horga G, Ghazzaoui R, Rosengard R, Ojeil N, Xu X, Slifstein M, Petrakis I, O'Malley SS, Krystal JH, Abi-Dargham A.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jul;3(7):591-598. doi: 10.1016/j.bpsc.2018.03.018. Epub 2018 Apr 21. Erratum in: Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jan;5(1):130.

8.

Long-range gamma phase synchronization as a compensatory strategy during working memory in high-performing patients with schizophrenia.

So RP, Kegeles LS, Mao X, Shungu DC, Stanford AD, Chen CA.

J Clin Exp Neuropsychol. 2018 Sep;40(7):663-681. doi: 10.1080/13803395.2017.1420142. Epub 2018 Feb 1.

PMID:
29388507
9.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.

Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA.

JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

10.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2017 Jul 25. doi: 10.1038/mp.2017.157. [Epub ahead of print]

PMID:
29155803
11.

Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis.

Caravaggio F, Brucato G, Kegeles LS, Lehembre-Shiah E, Arndt LY, Colibazzi T, Girgis R.

J Nerv Ment Dis. 2017 Nov;205(11):893-895. doi: 10.1097/NMD.0000000000000736.

12.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2018 Jun;23(6):1506-1511. doi: 10.1038/mp.2017.107. Epub 2017 May 16. Erratum in: Mol Psychiatry. 2017 Jul 25;:.

13.

Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Caravaggio F, Kegeles LS, Wilson AA, Remington G, Borlido C, Mamo DC, Graff-Guerrero A.

Synapse. 2016 Nov;70(11):453-60. doi: 10.1002/syn.21920. Epub 2016 Jul 11.

14.

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):31-42. doi: 10.1016/j.biopsych.2016.03.2104. Epub 2016 Mar 31. Review.

15.

Brain γ-aminobutyric acid (GABA) detection in vivo with the J-editing (1) H MRS technique: a comprehensive methodological evaluation of sensitivity enhancement, macromolecule contamination and test-retest reliability.

Shungu DC, Mao X, Gonzales R, Soones TN, Dyke JP, van der Veen JW, Kegeles LS.

NMR Biomed. 2016 Jul;29(7):932-42. doi: 10.1002/nbm.3539. Epub 2016 May 13.

16.

Brain GABA Function and Psychosis.

Kegeles LS.

Am J Psychiatry. 2016 May 1;173(5):448-9. doi: 10.1176/appi.ajp.2016.16020165. No abstract available.

PMID:
27133403
17.

Deficits in striatal dopamine release in cannabis dependence.

van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Ojeil N, Kegeles LS, Xu X, Vadhan NP, Volkow ND, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2017 Jan;22(1):68-75. doi: 10.1038/mp.2016.21. Epub 2016 Mar 22.

18.

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA.

J Psychopharmacol. 2016 May;30(5):428-35. doi: 10.1177/0269881116636120. Epub 2016 Mar 10.

PMID:
26966119
19.

A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ.

Mol Psychiatry. 2016 Mar;21(3):320-7. doi: 10.1038/mp.2015.83. Epub 2015 Aug 18.

20.

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P, Moore H, Shungu DC, Simpson HB.

Psychiatry Res. 2015 Aug 30;233(2):141-7. doi: 10.1016/j.pscychresns.2015.06.001. Epub 2015 Jun 6.

21.

Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy.

Simpson HB, Kegeles LS, Hunter L, Mao X, Van Meter P, Xu X, Kimeldorf MB, Pearlstein SL, Slifstein M, Shungu DC.

Psychiatry Res. 2015 Apr 30;232(1):65-70. doi: 10.1016/j.pscychresns.2015.01.009. Epub 2015 Feb 3.

22.

Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ.

Psychopharmacology (Berl). 2014 Oct;231(21):4231-40. doi: 10.1007/s00213-014-3566-6. Epub 2014 Apr 30.

23.

GABA level, gamma oscillation, and working memory performance in schizophrenia.

Chen CM, Stanford AD, Mao X, Abi-Dargham A, Shungu DC, Lisanby SH, Schroeder CE, Kegeles LS.

Neuroimage Clin. 2014 Mar 20;4:531-9. doi: 10.1016/j.nicl.2014.03.007. eCollection 2014.

24.

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Schizophr Res. 2014 Feb;152(2-3):325-32. doi: 10.1016/j.schres.2013.12.013. Epub 2014 Jan 11. Review.

25.

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.

Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Mol Psychiatry. 2014 Jan;19(1):20-9. doi: 10.1038/mp.2013.136. Epub 2013 Oct 29. Review.

PMID:
24166406
26.

Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy.

Martinez D, Slifstein M, Nabulsi N, Grassetti A, Urban NB, Perez A, Liu F, Lin SF, Ropchan J, Mao X, Kegeles LS, Shungu DC, Carson RE, Huang Y.

Biol Psychiatry. 2014 Jan 15;75(2):165-71. doi: 10.1016/j.biopsych.2013.06.026. Epub 2013 Sep 12.

27.

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB.

Neuropsychopharmacology. 2013 Nov;38(12):2475-83. doi: 10.1038/npp.2013.150. Epub 2013 Jun 19.

28.

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA.

Neuropsychopharmacology. 2013 Jun;38(7):1245-52. doi: 10.1038/npp.2013.23. Epub 2013 Jan 16.

29.

Striatal dopamine release in schizophrenia comorbid with substance dependence.

Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A.

Mol Psychiatry. 2013 Aug;18(8):909-15. doi: 10.1038/mp.2012.109. Epub 2012 Aug 7.

30.

Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy.

Simpson HB, Shungu DC, Bender J Jr, Mao X, Xu X, Slifstein M, Kegeles LS.

Neuropsychopharmacology. 2012 Nov;37(12):2684-92. doi: 10.1038/npp.2012.132. Epub 2012 Aug 1.

31.

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M.

Neuropsychopharmacology. 2012 May;37(6):1465-73. doi: 10.1038/npp.2011.332. Epub 2012 Feb 22.

32.

Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC.

Arch Gen Psychiatry. 2012 May;69(5):449-59. doi: 10.1001/archgenpsychiatry.2011.1519. Epub 2012 Jan 2.

PMID:
22213769
33.

Increased prefrontal cortical D₁ receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112.

Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M.

J Psychopharmacol. 2012 Jun;26(6):794-805. doi: 10.1177/0269881111409265. Epub 2011 Jul 18.

PMID:
21768159
34.

Maternal-fetal blood incompatibility and neuromorphologic anomalies in schizophrenia: Preliminary findings.

Freedman D, Deicken R, Kegeles LS, Vinogradov S, Bao Y, Brown AS.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 1;35(6):1525-9. doi: 10.1016/j.pnpbp.2011.04.012. Epub 2011 May 3.

35.

Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.

Rodriguez CI, Kegeles LS, Flood P, Simpson HB.

J Clin Psychiatry. 2011 Apr;72(4):567-9. doi: 10.4088/JCP.10l06653. No abstract available.

36.

Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.

Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Abi-Dargham A, Laruelle M.

J Psychopharmacol. 2011 Jun;25(6):734-43. doi: 10.1177/0269881110388329. Epub 2010 Nov 25.

PMID:
21109614
37.

(99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.

Devanand DP, Van Heertum RL, Kegeles LS, Liu X, Jin ZH, Pradhaban G, Rusinek H, Pratap M, Pelton GH, Prohovnik I, Stern Y, Mann JJ, Parsey R.

Am J Geriatr Psychiatry. 2010 Nov;18(11):959-72. doi: 10.1097/JGP.0b013e3181ec8696.

38.

Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

Bullich S, Slifstein M, Passchier J, Murthy NV, Kegeles LS, Kim JH, Xu X, Gunn RN, Herance R, Gispert JD, Gutiérrez A, Farré M, Laruelle M, Catafau AM.

Mol Imaging Biol. 2011 Aug;13(4):776-84. doi: 10.1007/s11307-010-0398-6.

PMID:
20730499
39.

Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride.

Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, Sakr E, Castillo F, Moadel T, O'Malley SS, Krystal JH, Abi-Dargham A.

Biol Psychiatry. 2010 Oct 15;68(8):689-96. doi: 10.1016/j.biopsych.2010.06.005. Epub 2010 Aug 3.

40.

Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.

Biol Psychiatry. 2010 Oct 1;68(7):634-41. doi: 10.1016/j.biopsych.2010.05.027. Epub 2010 Jul 31.

41.

Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.

Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M.

Arch Gen Psychiatry. 2010 Mar;67(3):231-9. doi: 10.1001/archgenpsychiatry.2010.10.

PMID:
20194823
42.

Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, Hackett E, Bae SA, Laruelle M, Abi-Dargham A.

Synapse. 2010 May;64(5):350-62. doi: 10.1002/syn.20734.

43.

Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.

Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M.

Biol Psychiatry. 2009 Jun 15;65(12):1091-3. doi: 10.1016/j.biopsych.2008.12.007. Epub 2009 Jan 23.

PMID:
19167701
44.

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.

Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.

Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16.

45.

[11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects.

Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A.

J Cereb Blood Flow Metab. 2007 Oct;27(10):1733-41. Epub 2007 Feb 21.

PMID:
17311076
46.

Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635.

Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A.

Psychopharmacology (Berl). 2006 Dec;189(2):155-64. Epub 2006 Sep 5.

PMID:
16953380
47.

Altered prefrontal dopaminergic function in chronic recreational ketamine users.

Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A.

Am J Psychiatry. 2005 Dec;162(12):2352-9.

PMID:
16330601
48.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
49.

Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.

van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, Narendran R, Van Heertum R, Laruelle M.

Neuropsychopharmacology. 2006 May;31(5):967-77.

50.

Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.

Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ.

Biol Psychiatry. 2004 May 15;55(10):1001-6.

PMID:
15121484

Supplemental Content

Loading ...
Support Center